Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

ain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the regulatory review of BELVIQ; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability of BELVIQ and pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever by any other regulatory agency; regulatory decisions in one territory may impact regulatory decisions in other territories and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional informa
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
2. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
9. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
10. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 Lucerne Biosciences, LLC announced ... of U.S. Patent Application No. 14/464,249 entitled "Method ... features claimed methods of "informing a user" that ... Binge Eating Disorder (,BED,)," including by reference to ... an advertisement," as well as by presentation of ...
(Date:3/5/2015)... DIEGO , March 5, 2015  Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its fourth quarter and full year ... March 16, 2015, before the market opens for ... will host a conference call to discuss the ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4
... TALLAHASSEE, Fla., March 11, 2011 The Florida Society ... latest facts on Oxycodone and Hydrocodone use in the ... available to the public or media.  Oxycodone dispensed in ... 2009 ARCOS report, US Census and FDA.Translation from grams ...
... 2011 Mylan Inc. (Nasdaq: MYL ) ... the company,s credit ratings, including the "Corporate Family Rating," ... Moody,s rating outlook is stable.   According ... trends accomplished through new product launches, a strong global ...
Cached Medicine Technology:Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2Moody's Upgrades Mylan 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 “ Pokemini ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... game. , Over the last couple of years, mobile ... to the game. For example, Candy Crush allows users to ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
(Date:3/6/2015)... New York, New York (PRWEB) March 06, 2015 ... tap dancing’s dazzling days on the grand stage, to the ... Legacy Dancers sparkle throughout with precision toe-tapping numbers and their ... and Karyn Tomczak deliver the rich history of tap dancing ... dance forms to come out of the United States. ...
(Date:3/6/2015)... As the Association of American ... 90,000 doctors by 2025 is updated this week and ... is proactively preparing by analyzing demographics and pursuing viable ... , Several factors including the increasing number of retiring ... the Affordable Care Act and an uneven distribution of ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... small capsule-shaped bacteria. The immune cells which help protect us ... in space travellers and it could be something to do ... (JSC) have been studying how immune cells behave in microgravity ... space on astronauts.// ,It has been found that astronauts ...
... approved the first pocket-sized EKG machine, so small ... ambulances, the emergency room - even a possible ... hand-held computer-based medical device, part of a growing ... equipment. ,Electrocardiograms, also called EKGs or ECGs, ...
... will probably be prescribed cholesterol-lowering drugs as a result ... cautions that the effects of those medications in that ... Cholesterol Education Program guidelines, about 15 million Americans between ... considered candidates taking statin group of drugs for ...
... claim that just by looking at a person's face could ... is that smokers age faster than non smokers.A study by ... genes responsible for a skin enzyme that breaks down collagen ... of the skin and maintains the elasticity of the skin. ...
... have devised that each cigarette cuts on average 12 minutes ... the difference in life expectancy between smokers and non-smokers and ... male smoker might consume in a lifetime. ,The researchers, ... expectancy from a major study of the impact of// smoking ...
... after a couple of drinks is a common problem for ... was a mystery until now.It may support the potentialities of ... College of Medicine and the Mayo Clinic in Minnesota say ... accused.// They found, in a study of healthy young adults, ...
Cached Medicine News:Health News:Immune cells halt round in space 2
... CSV- lOOOHGT instrument provides standardized glare testing. It ... test faces for the evaluation of glare disability. ... precisely calibrated to simulate two on-coming halogen car ... The glare level can be adjusted to simulate ...
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: